logo
Share SHARE
FONT-SIZE Plus   Neg

Corcept Therapeutics Q4 Loss Widens

Corcept Therapeutics Inc. (CORT) reported a fourth-quarter net loss of $9.9 million, or $0.12 per share, compared to a net loss of $7.1 million, or $0.10 per share, for the fourth quarter of 2010.

Research and development expenses increased to $6.6 million, from $4.7 million in the year ago quarter.

During the comparable periods, research and development expenses increased primarily due to higher costs associated with the submission and prosecution of our NDA for Korlym, purchase of Korlym's active pharmaceutical ingredient, manufacture of Korlym tablets and manufacturing development activities.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Electric car maker Tesla Motors Inc. (TSLA), Wednesday reported a loss for the fourth quarter that was narrower than last year. The company said it expects to start volume production of Model 3 by September. Palo Alto, California-based Tesla reported fourth-quarter loss of $121.3 million or $0.78... Canada based Maple Leaf Foods Inc. Wednesday said it has reached a definitive agreement with Brynwood Partner VI L.P. for the acquisition of Lightlife Foods Inc. The deal would be worth $140 million plus other costs. Light is a brand in U.S. for refrigerated plant based protein foods. A hedge fund is an alternative investment fund that uses pooled funds from accredited individuals or institutional investors and invests these funds in different assets with a goal of generating high returns. Hedge funds are generally accessible only to accredited or qualified investors. They cannot...
comments powered by Disqus
Follow RTT